Curium™ is pleased to announce that it has prevailed in the patent dispute brought by Novartis subsidiary Advanced Accelerator Applications against Curium™ concerning Curium’s Lutetium Lu 177 dotatate ...
Completion of patient dosing in the registrational Phase 2 clinical trial for 64 Cu-PSMA-I&T - a PET radiopharmaceutical targeting ...
The acquisition of Nucleis will: Enhance Curium's PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of ...
LONDON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added ...
This week, we meet the element curium, which has the atomic symbol Cm and the atomic number 96. This element was named in honour of Marie and Pierre Curie, who discovered the element, radium. The ...
The MarketWatch News Department was not involved in the creation of this content. -- A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic ...
Curium’s strategic investment of over €32 million will establish a European production line for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer ...
The recapitalization will accelerate Curium’s strategy to launch innovative, life-changing diagnostic and therapeutic solutions for cancer patients around the world BOSTON, Nov. 20, 2025 (GLOBE ...
Actinides are a group of heavy, radioactive elements that include uranium, plutonium, americium, curium, berkelium and californium. Understanding how these elements bond with other atoms (known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results